A20 (TNFAIP3) Distinguishes Relapse from Remission in Pediatric Patients with Monophasic MOGAD: Preliminary Results.

MLA

Lechner, C., et al. “A20 (TNFAIP3) Distinguishes Relapse from Remission in Pediatric Patients with Monophasic MOGAD: Preliminary Results.” Neuropediatrics, vol. 54, Oct. 2023, pp. S1–32. EBSCOhost, https://doi.org/10.1055/s-0043-1777141.

APA

Lechner, C., Saxena, S., Lokhande, H., Breu, M., Eisenkölbl, A., Karenfort, M., Klein, A., Leiz, S., Preisel, M., Rooney, T., Rosso, M., Schimmel, M., Wendel, E. M., Reindl, M., Baumann, M., Rostasy, K., & Chitnis, T. (2023). A20 (TNFAIP3) Distinguishes Relapse from Remission in Pediatric Patients with Monophasic MOGAD: Preliminary Results. Neuropediatrics, 54, S1–S32. https://doi.org/10.1055/s-0043-1777141

Chicago

Lechner, C., S. Saxena, H. Lokhande, M. Breu, A. Eisenkölbl, M. Karenfort, A. Klein, et al. 2023. “A20 (TNFAIP3) Distinguishes Relapse from Remission in Pediatric Patients with Monophasic MOGAD: Preliminary Results.” Neuropediatrics 54 (October): S1–32. doi:10.1055/s-0043-1777141.